NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel carbohydrate compounds, today announced it has signed an agreement with CESAR, the Central European Society for Anticancer Drug Research, to recruit biliary cancer patients in Germany. Up to six hospitals will be recruited for the Company’s Phase II, first line, biliary duct cancer trial. Two clinical sites in the U.S. are currently participating in this trial.
